Transforming the Lives of Patients with Diabetes

ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte's innovative products are based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01™), with subcutaneous implantation in a retrievable medical device (Encaptra® cell delivery system). Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte's goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence. If successful, ViaCyte’s products will relieve patients of both the acute challenges and risks, as well as the long-term complications, associated with diabetes. ViaCyte has received substantial financial, scientific, advocacy, and technical support from both the California Institute for Regenerative Medicine (CIRM) and JDRF.

ViaCyte’s Product Candidates for Diabetes

ViaCyte is developing islet cell replacement therapy for insulin-requiring diabetes. Our two products in clinical research deploy the same active component, PEC-01 Cells, but with different delivery technologies and addressing the unmet needs of different patient groups.

Watch More Videos

Hope for Patients with Diabetes

The Human Trial is an independent, feature-length documentary that is in the works, currently following ViaCyte’s quest to develop what might become a functional cure for type 1 diabetes (T1D).

Watch More Videos

Recent News

Our Partners